Jazz Pharmaceuticals plc
NASDAQ:JAZZ · NASDAQ Global Select
+$0.05 today
Vol 1.91M · Avg 0.92M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:JAZZ · Revenue to Net Income
Key Ratios
Analysis
$4.4B of revenue converted into $29.5M of net income for the selected period. Gross margin is 83.8% and net margin is -0.5%, showing how much revenue survives after costs and taxes. EPS is $0.11, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B +4.9% | $4.1B +6.1% | $3.8B +4.8% | $3.7B +18.3% | $3.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $503.3M +12.9% | $445.7M +2.3% | $435.6M -19.4% | $540.5M +22.6% | $440.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.8B +3.9% | $3.6B +6.6% | $3.4B +9.0% | $3.1B +17.5% | $2.7B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 88.2% -0.8pp | 89.0% +0.4pp | 88.6% +3.4pp | 85.2% -0.5pp | 85.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $782.7M -11.5% | $884.0M +4.0% | $849.7M +43.9% | $590.5M +16.7% | $505.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.8B +30.6% | $1.4B +3.1% | $1.3B -5.2% | $1.4B -2.4% | $1.5B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.5B +21.8% | $2.9B +3.1% | $2.8B -11.4% | $3.2B +28.2% | $2.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $542.0M -17.9% | $660.1M +3.3% | $638.7M +1.5% | $629.5M +13.9% | $552.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $108.5M -92.9% | $1.5B +5.0% | $1.4B -1.3% | $1.5B +42.9% | $1.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 2.5% -34.9pp | 37.4% -0.4pp | 37.8% -2.3pp | 40.1% +6.9pp | 33.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $224.4M -68.7% | $716.6M +23.9% | $578.6M +983.0% | -$65.5M -138.5% | $170.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 5.3% -12.4pp | 17.6% +2.5pp | 15.1% +16.9pp | -1.8% -7.3pp | 5.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $195.1M -18.1% | $238.1M -17.7% | $289.4M +0.4% | $288.2M +3.4% | $278.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$853.0M -244.0% | -$247.9M +12.6% | -$283.7M +10.6% | -$317.2M -11.7% | -$283.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$628.6M -234.1% | $468.7M +58.9% | $294.9M +177.1% | -$382.7M -237.0% | -$113.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -14.7% -26.2pp | 11.5% +3.8pp | 7.7% +18.2pp | -10.5% -6.8pp | -3.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$272.4M -198.0% | -$91.4M +23.8% | -$119.9M +24.4% | -$158.6M -173.4% | $216.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$356.1M -163.6% | $560.1M +35.0% | $414.8M +285.1% | -$224.1M +31.9% | -$329.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -8.3% -22.1pp | 13.8% +2.9pp | 10.8% +16.9pp | -6.1% +4.5pp | -10.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$6 -164.5% | $9 +38.3% | $7 +283.0% | -$4 +35.0% | -$6 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$6 -167.5% | $9 +41.8% | $6 +270.4% | -$4 +35.0% | -$6 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $61.0M -1.4% | $61.8M -2.3% | $63.3M +1.2% | $62.5M +4.8% | $59.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $61.0M -7.6% | $66.0M -8.4% | $72.1M +15.2% | $62.5M +4.8% | $59.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$12.98B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.52B
Cytokinetics, Incorporated
NASDAQ:CYTK
$9.72B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.13B
Merus N.V.
MRUS
$6.83B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.57B
Abivax S.A.
NASDAQ:ABVX
$6.57B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.05B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$213.48M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does JAZZ generate?
Jazz Pharmaceuticals plc (JAZZ) reported $4.27B of revenue in fiscal 2025.
Is JAZZ profitable?
Jazz Pharmaceuticals plc (JAZZ) reported -$356,148,000.00 of net income, with a net margin of -8.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.